Trial Profile
A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2010
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Cephalon
- 24 Aug 2010 Results published in the Journal of Clinical Psychiatry.
- 30 Apr 2009 Results presented at the 61st Annual Meeting of the American Academy of Neurology (AAN 2009).
- 04 Feb 2008 Status changed from in progress to completed. Updated from ClinicalTrials.gov.